Skip to main content

Advertisement

Table 2 Overview of treatment, artemisinin combination treatment dosing and formulation

From: Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data

  Treatment Dosing
  n evaluated N (%) n evaluated Partner drug dose median (Range) Artemisinin derivative dose median (Range) Underdosed n (%)
AL 48840 13217 (27 %) 13086 68.6 (8.9–144.0) 11.4 (1.5–24.0) 1008 (8.3 %)
AS-AQ 48840 8488 (17 %) 8395 31.9 (10.0–91.8) 12.4 (4.0–52.6)  
AS-AQ formulation:       
 Co-blistered nFDC 8488 573 (7 %) 573 37.4 (14.8–91.8) 13.5 (4.8–30.0)  
 FDC 8488 4278 (50 %) 4262 32.4 (14.5–81.0) 12.0 (5.4–30.0) 2 (0.1 %)
 nFDC 8488 3637 (43 %) 3560 30.1 (10.0–60.0) 12.5 (4.0–52.6)  
AS-MQ 48840 5198 (11 %) 4535 25.0 (4.2–85.0) 12.0 (2.3–62.1) 38 (0.8 %)
DP 48840 6453 (13 %) 6315 53.3 (14.5–182.9) 6.7 (1.8–22.9) 1488 (23.6 %)
Other, including non-ACT 48840 15484 (32 %)     
  1. AL, Artemether-Lumefantrine; AS-AQ, Artesunate-Amodiaquine; AS-MQ, Artesunate-Mefloquine; DP, Dihydroartemisinin-piperaquine; nFDC, Non-fixed dose combination, FDC, Fixed dose combination; Underdosed defined as ≤ 8.4 mg/kg artemether dose in AL, < 6 mg/kg dose of artesunate or DHA in other regimens [19]